60 yo, 2.1-cm node-neg IDC, ER+/HER2-neg adj TC + AI: Systemic Tx if chest wall recurrence 2 y later and NED?
60 yo woman, s/p mastectomy for a 2.1-cm IDC, negative nodes. Patient receives TC followed by anastrozole, but 2 years after starting anastrozole a small lesion is removed from the chest wall that proves to be a recurrence. No other disease is detected clinically or on imaging. Both the primary tumor and the recurrence are ER-positive/HER2-negative. What systemic treatment would you recommend?
Aebi S et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). San Antonio Breast Cancer Symposium 2012;Abstract S3-2.
Barrios C et al. The sequential use of endocrine treatment for advanced breast cancer: Where are we? Ann Oncol 2012;23(6):1378-86. Abstract
Blum JL et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2012;136(3):777-88. Abstract
Goldstein LJ et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26(25):4092-9. Abstract
Jankowitz RC et al. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. Breast 2013;22S2:S165-70. Abstract
Kaufman PA et al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. San Antonio Breast Cancer Symposium 2012;Abstract S6-6.